LOQTORZI toripalimab-tpzi Updated Nov 9
LOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.
- LOQTORZI is the only FDA-approved treatment specifically for nasopharyngeal carcinoma, a niche with limited competition and a clear medical need.
- Six-year JUPITER-02 follow-up data showed LOQTORZI plus chemotherapy nearly doubled median overall survival (64.8 months vs chemotherapy alone), with a 38% lower risk of death.
- Revenue is growing: Q2 2026 LOQTORZI net sales of $13.6M were up 15% sequentially and 92% year-over-year, with management guiding $57M-$62M for full-year 2026.
- NPC is a rare cancer, limiting LOQTORZI's peak sales potential to an estimated $150M-$200M by mid-2028, which is modest for a commercial biotech.
- The PD-1 inhibitor market is intensely competitive, dominated by Merck's Keytruda and Bristol Myers' Opdivo, which have broad label approvals across many cancer types.
- Coherus priced LOQTORZI at a roughly 20% discount to Keytruda, suggesting pricing pressure in the PD-1 class.